Abstract Details

Title Use of Rituxan in Autoimmune Neuromuscular Diseases and Outcomes in 3 Key Disease Groups

Topic Muscle Disease/Neuromuscular Junction

Presentation(s) P02 - (-)

Poster/Presentation
Number 194

Objective

Background BACKGROUND: The three common categories of autoimmune neuromuscular diseases include, inflammatory myopathies, myasthenia gravis and CIDPN. These disease are considered treatable and even have the potential to go into remission. However many patients improve with only multiple therapies including steroids, azathioprine, IVIG and plasmapheresis on a chronic basis. Rituxan is being increasingly used in order to improve the clinical status in those patients who either do not repond or respond but remain dependent upon these therapies longterm.

Design/Methods DESIGN/METHODS: This study is a description of the cases that received Rituxan and the response and lack of response as measured by clinical symptoms and dependence upon other therapies.

Results RESULTS: Patietns with inflammatory myopathies responded significantly to rituxan allowing a decrease in other therapies. Patients with myasthenia gravis had a dramatic improvement in clinical symptoms and were able to reach minimal clinical symptomatology or complete remission combined with withdrawal of other therapies particularly IVIG and Plasmapheresis. However little to no reponse was seen in patietns with CIPDN leading to all patients with this disorder to continue previous therapy.

Conclusions CONCLUSIONS: Rituxan can be safely recommended for treatment of inflammatories and myasthenia gravis however is not recommended for treatment of CIDPN based on our local experience.

Authors/Disclosures
Karine Garneau, MD (CHUM) PRESENTER	No disclosure on file
Angela L. Genge, MD (Mcgill University)	Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AL-S Pharma. Dr. Genge has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Genge has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Quralis. Dr. Genge has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MTPA. Dr. Genge has received personal compensation in the range of $0-$499 for serving as a Consultant for WAVE. Dr. Genge has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for eikonizo. Dr. Genge has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for rapa.
	No disclosure on file

��ɫ��

��ɫ��